[{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"PvP Biologics \/ Takeda","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Takeda"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"Il-2 mutein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"HDP","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABI-M201","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pharmaceuticals \/ Gossamer"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie"},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"OPL-002","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oppilan Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner International \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IMU-856","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Not Applicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Not Applicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Not Applicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-301","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CALY-002","moa":"IL-15","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Calypso Biotech SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Not Applicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Pfizer"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Olanzapine","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"transdermal patch","sponsorNew":"Starton Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.19,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ SVB Leerink"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Lyophilised powder for intravenous","sponsorNew":"CordenPharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CordenPharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Bovine Intestinal Alkaline Phosphatase","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Not Applicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Human Monoclonal Antibody","moa":"LIGHT","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Horizon Technology","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Horizon Technology"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Origo Biopharma","sponsor":"AgomAb Therapeutics N.V","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Origo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origo Biopharma \/ Agomab","highestDevelopmentStatusID":"6","companyTruncated":"Origo Biopharma \/ Agomab"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MDGN-002","moa":"LIGHT","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4Beta7 Integrin","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Not Applicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"Kv1.3 channel","graph1":"Gastroenterology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw Research \/ Eli Lilly"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"ORG-129","moa":"ALK-5","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"EQ102","moa":"IL15\/IL-21","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"T21","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FB-001","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Federation Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Federation Bio \/ Not Applicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Not Applicable"},{"orgOrder":0,"company":"Suono Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SUO-2002","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Suono Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio \/ Not Applicable"},{"orgOrder":0,"company":"Cellf BIO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Autologous Bioengineered Internal Anal Sphincter","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cellf BIO \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Napo Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Napo Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ORG-129","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ent001","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ATH-063","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Athos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IMU-856","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Adiso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MAP 315","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"Microba Life Sciences \/ Bacthera","highestDevelopmentStatusID":"6","companyTruncated":"Microba Life Sciences \/ Bacthera"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"T21","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CEL383","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Not Applicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"FXR314","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Organovo Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Not Applicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Not Applicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Aclipse Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lobeglitazone","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Aclipse Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Aclipse Therapeutics"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ATI-2138","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"ORG-129","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"Napo EU","sponsor":"Quadri Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Quadri Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Quadri Pharmaceuticals"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Adiso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DONQ52","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CALY-002","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"HTL0033744","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Not Applicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Not Applicable"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"ATH-063","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ US Naval Medical Research Command"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naronapride","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"","sponsorNew":"Organovo Holdings \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Jaguar Health"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CEL383","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Celsius Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MTX-101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Mozart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SPY001","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Spyre Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"}]
Find Gastroenterology Drugs in Phase I Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Quotient Sciences- Molecule to Cure. Fast.
